Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2009-01-29
2011-11-29
Saeed, Kamal (Department: 1622)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S563000, C514S564000, C546S300000, C562S442000, C562S439000
Reexamination Certificate
active
08067445
ABSTRACT:
Described herein are compounds that are antagonists of PGD2receptors. Also described are pharmaceutical compositions and medicaments that include the compounds described herein that are antagonists of PGD2receptors. Also described herein are methods of using such antagonists of PGD2receptors, alone and in combination with other compounds, for treating respiratory, cardiovascular, and other PGD2-dependent or PGD2-mediated conditions or diseases.
REFERENCES:
patent: 5239084 (1993-08-01), Guerry et al.
patent: 5334598 (1994-08-01), Bagley et al.
patent: 5668176 (1997-09-01), Bagley et al.
patent: 5827868 (1998-10-01), Misra et al.
patent: 6617351 (2003-09-01), Arnold et al.
patent: 6884593 (2005-04-01), Hirai et al.
patent: 7005440 (2006-02-01), Jayyosi et al.
patent: 7144913 (2006-12-01), Wang et al.
patent: 7205329 (2007-04-01), Chien et al.
patent: 2001/0047027 (2001-11-01), Labelle et al.
patent: 2002/0198251 (2002-12-01), Sundermann et al.
patent: 2004/0214888 (2004-10-01), Matsura et al.
patent: 2005/0154044 (2005-07-01), Beaulieu et al.
patent: 2005/0171143 (2005-08-01), Tanimoto et al.
patent: 2005/0272756 (2005-12-01), Leblanc et al.
patent: 2006/0100425 (2006-05-01), Bennani et al.
patent: 2006/0106081 (2006-05-01), Bennani et al.
patent: 2007/0155726 (2007-07-01), Arzaiz et al.
patent: 2008/0167378 (2008-07-01), Fukatsu et al.
patent: 2008/0306109 (2008-12-01), Hynd et al.
patent: 2009/0186923 (2009-07-01), Armer et al.
patent: 2009/0197959 (2009-08-01), Hutchinson et al.
patent: 2010/0004331 (2010-01-01), Hutchinson et al.
patent: 2010/0081673 (2010-04-01), Hutchinson et al.
patent: 2010/0113503 (2010-05-01), Hutchinson et al.
patent: 2010/0173313 (2010-07-01), Bain et al.
patent: 2010/0280049 (2010-11-01), Stearns et al.
patent: 2010/0298368 (2010-11-01), Stearns et al.
patent: 2011/0021573 (2011-01-01), Hutchinson et al.
patent: 2011/0034558 (2011-02-01), Brittain et al.
patent: 2011/0098352 (2011-04-01), Hutchinson et al.
patent: 1170594 (2002-01-01), None
patent: 2460597 (2010-04-01), None
patent: 2461629 (2010-05-01), None
patent: 2463788 (2010-12-01), None
patent: 2004-182657 (2004-07-01), None
patent: WO-95-03044 (1995-02-01), None
patent: WO-99-11605 (1999-03-01), None
patent: WO-03-006011 (2003-01-01), None
patent: WO-2004-035543 (2004-04-01), None
patent: WO-2004-058164 (2004-07-01), None
patent: WO-2004-096777 (2004-11-01), None
patent: WO-2005-040114 (2005-05-01), None
patent: WO-2005-044260 (2005-05-01), None
patent: WO-2005-051373 (2005-06-01), None
patent: WO-2005-100298 (2005-10-01), None
patent: WO-2005-105727 (2005-10-01), None
patent: WO-2006-005909 (2006-01-01), None
patent: WO-2006-014357 (2006-02-01), None
patent: WO-2006-18325 (2006-02-01), None
patent: WO-2006-037982 (2006-04-01), None
patent: WO-2006-052798 (2006-05-01), None
patent: WO-2006-056854 (2006-06-01), None
patent: WO-2006-070325 (2006-07-01), None
patent: WO-2006-125596 (2006-11-01), None
patent: WO-2007-037187 (2007-04-01), None
patent: WO-2007-039736 (2007-04-01), None
patent: WO-2007-068894 (2007-06-01), None
patent: WO-2007-088996 (2007-08-01), None
patent: WO-2007-107772 (2007-09-01), None
patent: WO-2007-144127 (2007-12-01), None
patent: WO-2008-017989 (2008-02-01), None
patent: WO-2008-024746 (2008-02-01), None
patent: WO-2008-082567 (2008-07-01), None
patent: WO-2008-137027 (2008-11-01), None
patent: WO-2008-156780 (2008-12-01), None
patent: WO-2009-004379 (2009-01-01), None
patent: WO-2009-044147 (2009-04-01), None
patent: WO-2009-089192 (2009-07-01), None
patent: WO-2009-099901 (2009-08-01), None
patent: WO-2009-099902 (2009-08-01), None
patent: WO-2009-102893 (2009-08-01), None
patent: WO-2009-108720 (2009-09-01), None
patent: WO-2009-145989 (2009-12-01), None
patent: WO-2010-003120 (2010-01-01), None
patent: WO-2010-037054 (2010-04-01), None
patent: WO-2010-037059 (2010-04-01), None
patent: WO-2010-039977 (2010-04-01), None
patent: WO-2010-042652 (2010-04-01), None
patent: WO-2010-057118 (2010-05-01), None
patent: WO-2011-014587 (2011-02-01), None
patent: WO-2011-014588 (2011-02-01), None
patent: WO-2011-017201 (2011-02-01), None
Lala et al., Role of nitric oxide in tumor progression: Lessons from experimental tumors, Cancer and Metastasis Reviews (1998), 17, 91-106.
Golub et al., Molecular Classification of Cancer: Class Discovery and Class Prediction by Gene Expression Monitoring, Science (1999), vol. 286, 531-537.
Arima, M., and Fukuda, T., “Prostaglandin D2receptors DP and CRTH2 in the pathogenesis of asthma,”Curr. Mol. Med.8, 365-375 (2008).
Hata, A.N. and Breyer, R.M., “Pharmacology and signaling of prostaglandin receptors: multiple roles in inflammation and immune modulation,”Pharmacol Ther.August;103(2):147-66 (2004).
Kostenis, E. and Ulven, T., “Emerging roles of DP and CRTH2 in allergic inflammation,”Trends Mol Med.April;12(4):148-58 (2008).
Medina, J. C. and Liu, J., “PGD2 Antagonists” Annual Reports in Medicinal Chemistry, vol. 41, 2006, pp. 221-235.
PCT/US09/32495 Written Opinion and Search Report dated Jun. 29, 2009.
PCT/US09/32499 Written Opinion and Search Report dated Jun. 29, 2009.
PCT/US09/32495 IPRP dated Aug. 3, 2010.
PCT/US09/32499 IPRP dated Aug. 3, 2010.
Pettipher, R. et al., “Antagonism of the prostaglandin D2 receptors DP1 and CRTH2 as an approach to treat allergic diseases,”Nature Drug Discovery6:313-325 (2007).
Science IP Structure Search dated Nov. 6, 2007.
Tirouvanziam, R., et al., “Profound functional and signaling changes in viable inflammatory neutrophils homing to cystic fibrosis airways,” Proc. Nat. Acad. Sci. USA105:4335-4339 (2008).
Ulven T et al,. “Targeting the prostaglandin D2 receptors DP and CRTH2 for treatment of inflammation”,Curr. Top. Med. Chem.2006;6(13):1427-44.
Crosignani et al., “Discovery of a new class of potent, selective, and orally bioavailable CRTH2(DP2) receptor antagonists for the treatment of allergic inflammatory diseases” J Med Chem 51:2227-2243 (2008).
Evans et al., “Seeing the future of bioactive lipid drug targets,” Nature Chem Biol 6:476-479 (2010).
Kim et al., “Regulation of Immune Cells by Eicosanoid Receptors,” TheScientificWorld Journal 7:1307-1328 (2007).
Ly and Bacon, “Small-molecule CRTH2 antagonists for the treatment of allergic inflammation: an overview,” Exp Opin Invest Drugs 14:769 (2005).
Pettipher et al., “The roles of the prostaglandin D(2) receptors DP(1) and CRTH2 in promoting allergic responses,” Br J Pharmacol 153:S191 (2008).
Pettipher et al., “Antagonists of the prostaglandin D2 receptor CRTH2,” Drug News Perspect 21:317-322 (2008).
Prieto et al., “Racemization in Suzuki couplings: a quantitative study using 4-hydroxyphenylglycine and tyrosine derivatives as probe molecules,” J Org Chem 72(3):1047-1049 (2007).
Sandham et al., “7-Azaindole-3-acetic acid derivatives: potent and selective CRTH2 receptor antagonists,” Bioorg Med Chem Lett 19:4794-4798 (2009).
Sandig et al., “Contrary prostaglandins: the opposing roles of PGD2 and its metabolites in leukocyte function,” J Leukocyte Biology 81:372-382 (2007).
Scott et al., “Discovery and optimization of a biphenylacetic acid series of prostaglandin D2 receptor DP2 antagonists with efficacy in a murine model of allergic rhinitis,” Bioorg Med Chem Ltrs (2011), doi: 10.1016fj.bmcl.2011.01.024.
Shrader et al., “Factor VIIa inhibitors: Gaining selectivity within the trypsin family,” Bioorg Med Chem Ltrs 16(6):1596-1600 (2006).
Srinivas et al., “Biaryl amino acid templates in place of D-Pro-L-Pro in cyclic beta-hairpin cationic antimicrobial peptidomimetics,” Organic & Biomolecular Chemistry 5(19):3100-3105 (2007).
Stearns et al., “Novel tricyclic antagonists of the prostaglandin D2 receptor DP2 with efficacy in a murine model of allergic rhinitis,” Bioorg Med Chem Ltrs 19:4647-4651 (2009).
Stebbins et al., “DP2 Receptor Antagonists: Novel Therapeutic Target for
Arruda Jeannie M.
Hutchinson John Howard
Roppe Jeffrey Roger
Scott Jill Melissa
Seiders Thomas Jon
Bianchi Kristin
Panmira Pharmaceuticals, LLC
Saeed Kamal
Wilson Sonsini Goodrich & Rosati
LandOfFree
N,N-disubstituted aminoalkylbiphenyl antagonists of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with N,N-disubstituted aminoalkylbiphenyl antagonists of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and N,N-disubstituted aminoalkylbiphenyl antagonists of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4260965